Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 51-60 of 108 for breast cancer

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  2. Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for Locally Advanced or Metastatic ER+/HER2− Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

    Jacksonville, FL, Scottsdale/Phoenix, AZ, Rochester, MN

  4. LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

    Rochester, MN

  5. RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel for Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

    Jacksonville, FL

  6. Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

    Jacksonville, FL, La Crosse, WI, Rochester, MN, Eau Claire, WI

  7. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    La Crosse, WI, Mankato, MN, Rochester, MN

  8. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. Assessing Breast Cancer Risk Perception in Hispanic, Black, and Black Hispanic Women

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  10. Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development

    Jacksonville, FL

.

Mayo Clinic Footer